Senti Bio Receives the US FDA’s Clearance on IND Application Submitted for SENTI-202 to Treat Hematologic Malignancies
Shots:
- Following the IND clearance, the company plans to initiate a P-I trial evaluating SENTI-202 in patients with hematologic malignancies across multiple sites in the US & Australia. Senti Bio expects to initiate the trial in 2024, treat 1st patient by Q2’24 & present efficacy data by YE 2024
- The trial will evaluate 2 dose levels of SENTI-202 incl. 1 or 1.5B SENTI-202 cells administered after lymphodepleting conditioning in adult patients with r/r CD33 and/or FLT3 expressing hematologic malignancies incl. acute myeloid leukemia (AML). The initial dosing will incl. 3 doses administered weekly
- SENTI-202 is a CAR-NL cell therapy designed to selectively target & eliminate CD33 and/or FLT3 expressing hematologic malignancies
Ref: Senti Bio | Image: Senti Bio
Related News:- Senti Bio Collaborates with BlueRock to Develop Gene Circuit Engineered Cell Therapies for Regenerative Medicine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
